August 2023: Nyra Medical appoints med tech industry veteran Lori Chmura as Chief Executive Officer

​ATLANTA, Aug. 8, 2023 /PRNewswire/ -- Nyra Medical, an innovative medical device company developing a next generation transcatheter mitral valve repair technology, announced the appointment of Lori Chmura as Chief Executive Officer and Board Director. Lori succeeds Dr Murali Padala, who founded the company and will assume the role of Chief Scientific Officer. (Read more...)

Feb 2023: Emory Univ awards Nyra significant event of the year award

Nyra Medical has an exclusive worldwide license to the CARLEN technology, from Emory University. In lieu of the licensing and the private financing raised by Nyra to advance this technology to clinical use and make a positive impact on heart failure patients, we are honored by this recognition.

Feb 2023: Nyra Medical is recognized by Georgia Bio and the CGHI

Georgia BIO awarded Nyra Medical with a golden helix award in lieu of its recent private financing. We are proud to be a part of this emerging ecosystem in the South East. Read more here...(https://www.einpresswire.com/article/616091954/the-center-for-global-health-innovation-names-2023-golden-helix-award-winners)

Jan 2023: Nyra Medical announces issuance of its second US patent

• Second patent on Nyra's novel approach to treat mitral regurgitation was issued by the USPTO
• Issued patent provides strong coverage for Nyra's unique way of deploying the implant onto the heart valve

Nov 2022: Nyra Medical announces $20M Series A financing

• ​Financing co-led by Vensana Capital and a Large, Global Medical Device Company
• Use of Proceeds to Advance Development of a Novel Catheter-based Solution for Mitral Regurgitation

 
ATLANTA, GA, November 22, 2022: Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the closing of a $20 million Series A financing. The round was co-led by Vensana Capital and a large, global medical device company, alongside additional investors Broadview Ventures, Epidarex Capital, and the Georgia Research Alliance Venture Fund. Proceeds from the financing will be used to support Nyra’s technology through early feasibility clinical studies (Read more)